BRPI0416920A - redução de cicatriz dérmica - Google Patents

redução de cicatriz dérmica

Info

Publication number
BRPI0416920A
BRPI0416920A BRPI0416920-4A BRPI0416920A BRPI0416920A BR PI0416920 A BRPI0416920 A BR PI0416920A BR PI0416920 A BRPI0416920 A BR PI0416920A BR PI0416920 A BRPI0416920 A BR PI0416920A
Authority
BR
Brazil
Prior art keywords
dermal scar
scar reduction
dermal
reduction
waf1
Prior art date
Application number
BRPI0416920-4A
Other languages
English (en)
Portuguese (pt)
Inventor
Danling Gu
Monica Zepeda
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Canji Inc filed Critical Canji Inc
Publication of BRPI0416920A publication Critical patent/BRPI0416920A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
BRPI0416920-4A 2003-11-24 2004-11-23 redução de cicatriz dérmica BRPI0416920A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US52499303P 2003-11-24 2003-11-24
PCT/US2004/039633 WO2005051971A1 (en) 2003-11-24 2004-11-23 Reduction of dermal scarring

Publications (1)

Publication Number Publication Date
BRPI0416920A true BRPI0416920A (pt) 2007-01-23

Family

ID=34632948

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0416920-4A BRPI0416920A (pt) 2003-11-24 2004-11-23 redução de cicatriz dérmica

Country Status (13)

Country Link
US (3) US7465442B2 (enExample)
EP (1) EP1692154A4 (enExample)
JP (2) JP4842139B2 (enExample)
KR (1) KR101167330B1 (enExample)
CN (2) CN100482674C (enExample)
AU (1) AU2004293474B2 (enExample)
BR (1) BRPI0416920A (enExample)
CA (1) CA2546287C (enExample)
IL (1) IL175603A (enExample)
NO (1) NO20062978L (enExample)
NZ (1) NZ546983A (enExample)
WO (1) WO2005051971A1 (enExample)
ZA (1) ZA200604147B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100482674C (zh) * 2003-11-24 2009-04-29 坎吉有限公司 皮肤瘢痕形成的减少
AU2009205429A1 (en) 2008-01-14 2009-07-23 Conventus Orthopaedics Inc. Apparatus and methods for fracture repair
US8796443B2 (en) 2008-09-22 2014-08-05 Rxi Pharmaceuticals Corporation Reduced size self-delivering RNAi compounds
EP2523614A4 (en) 2010-01-15 2017-02-15 Conventus Orthopaedics, Inc. Rotary-rigid orthopaedic rod
CN105534561B (zh) 2010-01-20 2018-04-03 康文图斯整形外科公司 用于骨接近和骨腔准备的装置及方法
JP2013521880A (ja) 2010-03-08 2013-06-13 コンベンタス オーソピディックス， インコーポレイテッド 骨インプラントを固定するための装置および方法
KR20180044433A (ko) 2010-03-24 2018-05-02 알엑스아이 파마슈티칼스 코포레이션 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭
EP3077050B1 (en) * 2013-12-04 2020-10-21 Phio Pharmaceuticals Corp. Methods for treatment of wound healing utilizing chemically modified oligonucleotides
AU2014362251B2 (en) 2013-12-12 2019-10-10 Conventus Orthopaedics, Inc. Tissue displacement tools and methods
US10900039B2 (en) 2014-09-05 2021-01-26 Phio Pharmaceuticals Corp. Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
SG11201808704YA (en) 2016-04-14 2018-11-29 Trizell Ltd Viral vector stabilization
WO2019010252A2 (en) 2017-07-04 2019-01-10 Conventus Orthopaedics, Inc. Apparatus and methods for treatment of a bone

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394370A (en) 1981-09-21 1983-07-19 Jefferies Steven R Bone graft material for osseous defects and method of making same
US4505266A (en) 1981-10-26 1985-03-19 Massachusetts Institute Of Technology Method of using a fibrous lattice
US4485097A (en) 1982-05-26 1984-11-27 Massachusetts Institute Of Technology Bone-equivalent and method for preparation thereof
JPH0662679B2 (ja) 1985-06-21 1994-08-17 新田ゼラチン株式会社 組織親和性コラ−ゲンとその製法
WO1992002247A1 (en) * 1990-08-01 1992-02-20 Chiron Ophthalmics, Inc. Method for treating corneal endothelial wounds
US5302706A (en) 1991-12-16 1994-04-12 Baylor College Of Medicine Senescent cell derived inhibitors of DNA synthesis
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5596079A (en) 1991-12-16 1997-01-21 Smith; James R. Mimetics of senescent cell derived inhibitors of DNA synthesis
KR100331363B1 (ko) 1992-10-16 2002-12-05 콜드 스프링 하버 래보레이토리 사이클린복합체재배열및그것과관련된용도
US6211334B1 (en) 1992-10-16 2001-04-03 Cold Spring Harbor Cell-cycle regulatory proteins, and uses related thereto
FR2702152B1 (fr) 1993-03-03 1995-05-24 Inst Nat Sante Rech Med Virus recombinants et leur utilisation en thérapie génique.
CA2170641C (en) 1993-08-30 2011-11-15 James R. Smith Senescent cell-derived inhibitors of dna synthesis
TW442569B (en) 1993-10-25 2001-06-23 Canji Inc Recombinant adenoviral vector
US6210939B1 (en) 1993-10-25 2001-04-03 Canji, Inc. Recombinant adenoviral vector and methods of use
EP0702730A4 (en) 1994-03-18 1997-05-07 Univ Utah Res Found COREWAY MUTTATIONS IN THE MTS GENE AND METHODS FOR DETECTING AN APPROXIMATION OF CANCER IN THE MTS GENE
ATE283355T1 (de) 1994-05-24 2004-12-15 Baylor College Medicine Mimetika von aus alternden zellen abgeleitete hemmer der dna synthese
US5851806A (en) * 1994-06-10 1998-12-22 Genvec, Inc. Complementary adenoviral systems and cell lines
US5631156A (en) 1994-06-21 1997-05-20 The University Of Michigan DNA encoding and 18 KD CDK6 inhibiting protein
WO1996012506A1 (en) 1994-10-24 1996-05-02 Baylor College Of Medecine Senescent cell-derived inhibitors of dna synthesis
US5827702A (en) 1994-10-31 1998-10-27 Genentech, Inc. Ocular gene therapy
GB9422175D0 (en) 1994-11-03 1994-12-21 Univ Dundee Indentification of the p21 waf1-pcna interaction site and therapeutic applications thereof
AU4602396A (en) 1994-12-22 1996-07-10 Regents Of The University Of Michigan, The Dna encoding a 20 kd cdk6 inhibiting protein
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
US5856094A (en) 1995-05-12 1999-01-05 The Johns Hopkins University School Of Medicine Method of detection of neoplastic cells
US6027742A (en) 1995-05-19 2000-02-22 Etex Corporation Bioresorbable ceramic composites
US5756283A (en) 1995-06-05 1998-05-26 The Trustees Of The University Of Pennsylvania Method for improved production of recombinant adeno-associated viruses for gene therapy
HUP9901908A3 (en) 1995-07-17 2000-02-28 Univ Texas P16 expression constructs and their application in cancer therapy
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
US5837511A (en) * 1995-10-02 1998-11-17 Cornell Research Foundation, Inc. Non-group C adenoviral vectors
US6001853A (en) * 1996-01-26 1999-12-14 The United States Of America As Represented By The Department Of Health And Human Services Hydroxylamine compositions for the prevention or retardation of cataracts
AU726584B2 (en) 1996-04-10 2000-11-09 University Of Southern California Gene therapy for proliferative vitreoretinopathy
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
US6274614B1 (en) 1997-02-11 2001-08-14 Qlt Inc. Methods, compositions and articles for reducing or preventing the effects of inflammation
JPH11205102A (ja) 1998-01-13 1999-07-30 Mitsubishi Electric Corp 遅延同期回路
US6489305B1 (en) 1998-05-08 2002-12-03 Canji, Inc. Methods and compositions for the treatment of ocular diseases
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
AU6919300A (en) * 1999-08-20 2001-03-19 University Of Pittsburgh Methods for in vivo gene delivery to sites of cartilage damage
US6579522B1 (en) * 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
US6667173B2 (en) 2000-12-01 2003-12-23 The Schepens Eye Research Institute Nucleic acids encoding platelet derived growth factor-alpha receptors
CN100482674C (zh) * 2003-11-24 2009-04-29 坎吉有限公司 皮肤瘢痕形成的减少
US7947267B2 (en) * 2004-10-08 2011-05-24 Potentia Pharmaceuticals, Inc. Viral complement control proteins for eye disorders

Also Published As

Publication number Publication date
KR20060127414A (ko) 2006-12-12
IL175603A (en) 2011-02-28
NZ546983A (en) 2009-05-31
EP1692154A4 (en) 2009-07-08
CN101507822B (zh) 2012-06-06
JP2007512377A (ja) 2007-05-17
AU2004293474A1 (en) 2005-06-09
JP4842139B2 (ja) 2011-12-21
ZA200604147B (en) 2007-11-28
US7465442B2 (en) 2008-12-16
WO2005051971A1 (en) 2005-06-09
US20090142397A1 (en) 2009-06-04
NO20062978L (no) 2006-06-26
AU2004293474B2 (en) 2010-12-23
CN101507822A (zh) 2009-08-19
US20050271623A1 (en) 2005-12-08
US20110129534A1 (en) 2011-06-02
CN100482674C (zh) 2009-04-29
US8329671B2 (en) 2012-12-11
JP2011207912A (ja) 2011-10-20
EP1692154A1 (en) 2006-08-23
CA2546287C (en) 2014-04-22
KR101167330B1 (ko) 2012-07-23
CA2546287A1 (en) 2005-06-09
CN1906205A (zh) 2007-01-31
IL175603A0 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
BRPI0416920A (pt) redução de cicatriz dérmica
WO2009026166A3 (en) Antiinfective flavonol compounds and methods of use thereof
BR0312957A (pt) Composto ou um sal farmaceuticamente aceitável deste, uso do mesmo, composição farmacêutica, e, método para produzir um efeito inibidor de 11betahsd1 em um animal de sangue quente, tal como o homem, em necessidade de tal tratamento
MXPA04001323A (es) Dihidro-3-halo-1h-pirazol-5-carboxilatos sustituidos, su preparacion y uso.
AU2003257937A1 (en) Methods and compositions for treatment of dermal conditions
BRPI0312331A2 (pt) composições de ácido hialurônico e métodos de emprego.
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
TW200724033A (en) Anthranilamide arthropodicide treatment
ATE476427T1 (de) Difluormethyl thiazolyl carboxanilide
BR0316375A (pt) Diazinopirimidinas
SE0301886D0 (sv) New use V
SE0301882D0 (sv) New use I
SE0301888D0 (sv) New use VII
WO2005000860A3 (en) Compositions and methods for treatment of disease with acetylated disaccharides
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE535510T1 (de) Benzylamine, verfahren zu ihrer herstellung und ihre verwendung als entzündungshemmende mittel
WO2002089799A3 (en) Use of dihydropyrazoles to increase erythropoietin and vasculari zation
TW200613308A (en) Cyclobutanetetracarboxylate compound and preparation method thereof
BRPI0415678A (pt) compostos de pirimidina para o tratamento de inflamação
BRPI0404824A (pt) Processos para preparar uma composição de polìmero, um polìmero multifuncional, e uma composição multifuncional para modificação de cabelos
EP2135622A3 (en) Compositions for providing an analgesic effect to the skin
AU2003218188A1 (en) Method of treating onychomycosis
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B15K Others concerning applications: alteration of classification

Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07H 21/04 , C12N 15/00 , C12N 15/09 , C12N 15/63 , C12N 15/85 , A61K 48/00

Ipc: A61K 48/00 (2006.01), C12N 15/00 (2006.01), C12N 1

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]